- The trend backdrop is active with a 3-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Volume is elevated versus the 13-week average, confirming attention.
CONCORDBIO
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Concord Biotech Limited · Healthcare · Biotechnology
Latest close
1,365 INR
-3.9%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 13.7% above the Trend Line and sits at 47.0% of its 52-week range. The latest completed week returned -3.9%, after a 5.2% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers. The latest news-sentiment score is 51/100.
Setup score
53
out of 100
Latest Close
1,365 INR
7 Aug 2026
1W Return
-3.9%
latest completed week
4W Return
5.2%
short-term follow-through
12W Return
20.2%
quarterly tape
Trend Breadth
5.8%
3 of 52 weeks active
Volume Ratio
1.9x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is weak, so confirmation is not yet broad enough.
- The share remains more than 20% below its 52-week high.
- Latest weekly return ranks in the weaker part of its sector group.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-3.9%
Latest completed week; four-week move 5.2%.
Indicator stack
14/71
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
51/100
35 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 13.7% above the Trend Line and sits at 47.0% of its 52-week range. The latest completed week returned -3.9%, after a 5.2% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.9x the 13-week average. Participation is unusually strong and confirms that the move is attracting attention.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.3612-week average 0.23
12-week confirmation
Trend active3/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership4/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.36Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 5.2% over four weeks, 20.2% over 12 weeks, and -14.0% over one year. The current trend has remained active for 3 consecutive weeks.
Performance by holding period
Active trend streak3 weeks
Active weeks in one year3
Trend breadth5.8%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.11Latest activity-pressure read.
Pressure change8.8%Four-week change in activity pressure.
Leadership3.61Latest relative-leadership reading.
RS change253.6%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality ranks strongly versus its universe; growth ranks weakly; valuation is expensive relative to peers.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength16/100Blend of value, momentum, and quality. Underlying universe rank 85; rank 1 is best.
Value9/100Relative valuation strength. Underlying universe rank 92; rank 1 is best.
Quality90/100Profitability and accounting quality. Underlying universe rank 11; rank 1 is best.
Momentum25/100Medium-term price momentum. Underlying universe rank 76; rank 1 is best.
Growth5/100Revenue and earnings growth. Underlying universe rank 96; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework20/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 55.0x Price divided by trailing earnings.
- Price / sales
- 13.5x Market value relative to trailing revenue.
- EV / EBITDA
- 34.0x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 1.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 76.7% Gross profit retained from each unit of revenue.
- Operating margin
- 27.8% Operating profit retained from revenue.
- Free-cash-flow margin
- 16.3% Free cash flow generated from revenue.
- Return on invested capital
- 10.9% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -11.3% Latest one-year revenue growth.
- EPS growth
- -29.8% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- 28.8% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 1.3% Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 1.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 35 relevant articles.
5 positive · 26 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-23.8%Distance below the 52-week high.
13-week volatility7.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher12 of 2614 weeks finished lower.
Best week+15.1%Week of 5 Jun.
Worst week-10.8%Week of 13 Feb.
Latest week-3.9%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains7
Flat weeks0
Modest losses7
Sharp losses7
Recent vol7.4%13-week weekly-return volatility.
Base vol6.1%52-week weekly-return volatility.
Up/down split22/30Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -4.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank28 / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Biotechnology
4-week rank3 / 12
Group average-2.7%
Trend breadth83.3%
Trend83.3%active weekly trend signals
MD75.0%positive activity pressure
RS58.3%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape48/100
Trend, activity pressure, participation, and risk combine to a 48/100 tape read.
Indicator analysis48/100Latest 12-week confirmation: trend 3/12, activity pressure 12/12, relative leadership 4/12.
Activity pressure 0.36; No reversal markers Factors35/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 28; Small Cap Core rank 87 SVQF20/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1268.0 of 1576 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 35 relevant articles.
Concord Biotech Limited Just Beat Revenue Estimates By 5.0% Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1,365 INR | -3.9% | 1,201 INR | 1,520 INR | 1.11 | 3.61 | 930.0K | On |
| 31 Jul 2026 | 1,421 INR | 13.8% | 1,199 INR | 1,521 INR | 1.09 | 8.30 | 1.1M | On |
| 24 Jul 2026 | 1,248 INR | -6.5% | 1,196 INR | 1,521 INR | 0.97 | -2.79 | 321.2K | On |
| 17 Jul 2026 | 1,335 INR | 2.9% | 1,199 INR | 1,523 INR | 1.04 | 0.70 | 506.6K | Off |
| 10 Jul 2026 | 1,297 INR | 2.3% | 1,199 INR | 1,524 INR | 1.02 | -2.35 | 671.0K | Off |
| 3 Jul 2026 | 1,267 INR | -0.9% | 1,201 INR | 1,526 INR | 1.01 | -5.42 | 116.1K | Off |
| 26 Jun 2026 | 1,278 INR | -2.2% | 1,206 INR | 1,527 INR | 0.99 | -4.26 | 0 | Off |
| 19 Jun 2026 | 1,307 INR | -3.4% | 1,210 INR | 1,529 INR | 0.89 | -2.52 | 282.2K | Off |
| 12 Jun 2026 | 1,354 INR | 11.9% | 1,214 INR | 1,531 INR | 0.85 | 1.98 | 358.9K | Off |
| 5 Jun 2026 | 1,210 INR | 15.1% | 1,219 INR | 1,532 INR | 0.67 | -8.72 | 207.8K | Off |
| 29 May 2026 | 1,051 INR | -8.9% | 1,226 INR | 1,534 INR | 0.59 | -21.96 | 636.7K | Off |
| 22 May 2026 | 1,153 INR | 1.6% | 1,239 INR | 1,537 INR | 0.64 | -15.72 | 554.4K | Off |
| 15 May 2026 | 1,135 INR | -3.3% | 1,249 INR | 1,540 INR | 0.18 | -17.12 | 684.9K | Off |
| 8 May 2026 | 1,174 INR | 2.8% | 1,262 INR | 1,543 INR | -0.09 | -16.51 | 1.2M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.